Acuson has completed its acquisition of Ecton, developer of a miniaturized echocardiography technology (SCAN 9/29/99). Mountain View, CA-based Acuson purchased Ecton of Plymouth Meeting, PA, for 1.4 million shares, currently worth about $17
Acuson has completed its acquisition of Ecton, developer of a miniaturized echocardiography technology (SCAN 9/29/99). Mountain View, CA-based Acuson purchased Ecton of Plymouth Meeting, PA, for 1.4 million shares, currently worth about $17 million, plus $4 million in cash. Ecton shareholders may also be entitled to an addition $17 million, depending on Ectons operating results through 2004.
Ecton now becomes the Small Systems division of Acuson and will remain in Plymouth Meeting, with president Michael Cannon stepping into the role of general manager. The Ecton group will continue to focus on the development and commercialization of its Cypress echocardiography system, a low-cost, compact, portable product that Acuson hopes will expand its presence in the low- and mid-range cardiovascular ultrasound market. Cypress already has Food and Drug Administration marketing clearance and will initially sell for $40,000 to $60,000, with the first shipments expected in the second half of this year.
In other news, Acuson received 510(k) clearance from the FDA to market its AcuNav diagnostic ultrasound catheter (SCAN 9/29/99). AcuNav is a miniaturized catheter designed to enable physicians to visualize images from inside the heart during diagnostic and therapeutic procedures without having to open the chest wall.
Acuson has a licensing agreement with the Mayo Clinic for AcuNav, which has been in development since 1991; the company and the clinic both hold a series of patents on the technology. Acuson expects to begin shipping AcuNav this quarter.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.